Alto Neuroscience Statistics
Share Statistics
Alto Neuroscience has 26.97M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 26.97M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 35 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 4.61M, so 17.11% of the outstanding shares have been sold short.
| Short Interest | 4.61M |
| Short % of Shares Out | 17.11% |
| Short % of Float | 20.99% |
| Short Ratio (days to cover) | 3.47 |
Valuation Ratios
The PE ratio is -15.33 and the forward PE ratio is -1.57.
| PE Ratio | -15.33 |
| Forward PE | -1.57 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | -7.76 |
| P/FCF Ratio | -16.41 |
| PEG Ratio | n/a |
Enterprise Valuation
Alto Neuroscience Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 15.22, with a Debt / Equity ratio of -0.14.
| Current Ratio | 15.22 |
| Quick Ratio | 15.22 |
| Debt / Equity | -0.14 |
| Total Debt / Capitalization | -15.95 |
| Cash Flow / Debt | -3.39 |
| Interest Coverage | -27.6 |
Financial Efficiency
Return on equity (ROE) is 0.51% and return on capital (ROIC) is 61.29%.
| Return on Equity (ROE) | 0.51% |
| Return on Assets (ROA) | -0.42% |
| Return on Capital (ROIC) | 61.29% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -465.45K |
| Employee Count | 78 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0, so Alto Neuroscience 's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 6.48 |
| 200-Day Moving Average | 11.32 |
| Relative Strength Index (RSI) | 34.25 |
| Average Volume (20 Days) | 802.03K |
Income Statement
In the last 12 months, Alto Neuroscience had revenue of $0 and earned -$36.30M in profits. Earnings per share was $-1.35.
| Revenue | 0 |
| Gross Profit | -373.00K |
| Operating Income | -37.81M |
| Net Income | -36.30M |
| EBITDA | -34.56M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.35 |
Balance Sheet
The company has $82.55M in cash and $9.99M in debt, giving a net cash position of $72.56M.
| Cash & Cash Equivalents | 82.55M |
| Total Debt | 9.99M |
| Net Cash | 72.56M |
| Retained Earnings | -76.97M |
| Total Assets | 191.61M |
| Working Capital | 169.51M |
Cash Flow
In the last 12 months, operating cash flow was -$33.45M and capital expenditures -$470.00K, giving a free cash flow of -$33.92M.
| Operating Cash Flow | -33.45M |
| Capital Expenditures | -470.00K |
| Free Cash Flow | -33.92M |
| FCF Per Share | -1.26 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
ANRO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -34.97% |
| FCF Yield | -32.58% |
Analyst Forecast
The average price target for ANRO is $10, which is 159.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 159.1% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | 1.49 |
| Piotroski F-Score | 4 |